Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome

Intensive Care Med. 1995 Mar;21(3):197-203. doi: 10.1007/BF01701472.

Abstract

Objective: To compare the effects of inhaled nitric oxide (NO) and an infusion of prostacyclin (PGI2) on right ventricular function in patients with severe acute respiratory distress syndrome (ARDS).

Design: Randomized prospective short-term study.

Setting: Post-surgical ICU in an university hospital.

Patients: 10 patients with severe ARDS referred to our hospital for intensive care.

Interventions: In random sequence the patients inhaled NO at a concentration of 18 parts per million (ppm) followed by 36 ppm, and received an intravenous infusion of PGI2 (4 ng.kg-1.min-1).

Measurements and results: Inhalation of 18 ppm NO reduced the mean (+/- SE) pulmonary artery pressure (PAP) from 33 +/- 2 to 28 +/- 1 mmHg (p = 0.008), increased right ventricular ejection fraction (RVEF), as assessed by thermodilution technique, from 28 +/- 2 to 32 +/- 2% (p = 0.005), decreased right ventricular end-diastolic volume index from 114 +/- 6 to 103 +/- 8 ml.m-2 (p = 0.005) and right ventricular end-systolic volume index from 82 +/- 4 to 70 +/- 5 ml.m-2 (p = 0.009). Mean arterial pressure (MAP) and cardiac index (CI) did not change significantly. The effects of 36 ppm NO were not different from the effects of 18 ppm NO. Infusion of PGI2 reduced PAP from 34 +/- 2 to 30 +/- 2 mmHg (p = 0.02), increased RVEF from 29 +/- 2 to 32 +/- 2% (p = 0.02). Right ventricular end-diastolic and end-systolic volume indices did not change significantly. MAP decreased from 80 +/- 4 to 70 +/- 5 mmHg (p = 0.03), and CI increased from 4.0 +/- 0.5 to 4.5 +/- 0.5 l.min-1.m-2 (p = 0.02).

Conclusions: Using a new approach to selective pulmonary vasodilation by inhalation of NO, we demonstrate in this group of ARDS patients that an increase in RVEF is not necessarily associated with a rise in CI. The increase in CI during PGI2 infusion is probably related to the systemic effect of this substance.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Child
  • Epoprostenol / administration & dosage
  • Epoprostenol / therapeutic use*
  • Extracorporeal Membrane Oxygenation
  • Female
  • Hemodynamics / drug effects
  • Humans
  • Infusions, Intravenous
  • Intensive Care Units
  • Male
  • Nitric Oxide / pharmacology
  • Nitric Oxide / therapeutic use*
  • Prospective Studies
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / physiopathology
  • Ventricular Function, Right / drug effects*

Substances

  • Nitric Oxide
  • Epoprostenol